You just read:

Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

News provided by

Convergence Pharmaceuticals

23 Sep, 2014, 07:58 BST